Israeli startup CytoReason, maker of a computation model to map and compare treatments, announced it secured $80 million in funding.
Pfizer, OurCrowd, NVIDIA and Thermo Fisher Scientific participated in the round.
WHAT IT DOES
CytoReason offers life sciences companies AI-enabled tools to gather data-driven and molecular-level insights to improve phase 2 success in clinical trials and optimize...
PocDoc secures CE mark for digital reader of lateral flow testing
Cambridge-based startup PocDoc has secured a CE mark for its artificial intelligence (AI) driven digital reader of lateral flow tests.
The cloud-based system allows any smartphone or tablet to become a universal digital reader, so healthcare organisations can roll out lateral flow testing for any disease or marker at scale.
Steve...
Israeli startup CytoReason today announced a partnership with Swiss multinational, Ferring Pharmaceuticals, to establish new treatments for inflammatory bowel disease (IBD).
This is the first collaboration between the two companies, pairing Ferring’s medical expertise with CytoReason’s artificial intelligence (AI) platform to build cell-centred disease models.
CytoReason is developing a...
